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Background: Recombinant human arginase (rhArg) has been developed for arginine deprivation therapy in cancer,
and is currently under clinical investigation. During pre-clinical evaluation, rhArg has exhibited significant anti-
proliferative activity in cancer cells deficient in the expression of ornithine carbamoyl transferase (OCT). Interestingly,
a variety of cancer cells such as melanoma and prostate cancer deficient in argininosuccinate synthetase (ASS) are
sensitive to arginine deprivation by arginine deiminase. In this study, we investigated levels of gene expression of
OCT and ASS, and the effects of rhArg in human prostate cancer cells: LNCaP (androgen-dependent), PC-3 and DU-
145 (both androgen-independent).
Results: Quantitative real-time PCR showed minimal to absent gene expression of OCT, but ample expression of
ASS expression in all 3 cell lines. Cell viability assay after 72-h exposure of rhArg showed all 3 lines had half maximal
inhibitory concentration less than or equal to 0.02 U/ml. Addition of ornithine to cell culture media failed to rescue
these cells from rhArg-mediated cytotoxicity.
Decreased phosphorylation of 4E-BP1, a downstream effector of mammalian target of rapamycin (mTOR), was noted
in DU-145 and PC-3 after exposure to rhArg. Moreover, there was no significant apoptosis induction after arginine
deprivation by rhArg in all 3 prostate cancer cell lines.
Conclusion: rhArg causes significant cytotoxicity in LNCaP, DU-145 and PC-3 prostate cancer cells which all
demonstrate decreased OCT expression. Inhibition of mTOR manifested by hypophosphorylation of 4E-BP1 suggests
autophagy is involved as alternative cell death mechanism. rhArg demonstrates a promising novel agent for
prostate cancer treatment.
Keywords: Arginase, Prostate cancer, Ornithine carbamoyl transferase, Argininosuccinate synthetase, Mammalian
target of rapamycin, AutophagyBackground
Arginine, a nonessential amino acid, is involved in many
biochemical processes besides protein synthesis, such as
urea cycle and biosyntheses of creatine, polyamine and ni-
tric oxide [1]. In human tissue, arginine is obtained via pro-
tein degradation and dietary intake. Additionally, normal
cells can synthesize arginine intracellularly from ornithine,
mediated by ornithine carbamoyl transferase (OCT) which
metabolizes ornithine and carbamoly phosphate into citrul-
line; argininosuccinate synthetase (ASS) and argininosucci-
nate lyase subsequently convert citrulline to arginine [2].* Correspondence: chsueh@llu.edu
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reproduction in any medium, provided the origOCT is highly expressed in liver and small intestine, and
catabolizes the conversion of ornithine to citrulline [3].
However, OCT expression in cancer and other normal tis-
sues is mostly down-regulated due to epigenetic changes
such as DNA hypermethylation [4].
For years, depletion of arginine has been shown to be an
effective and promising anti-cancer treatment in vitro and
in vivo [5,6]. By culturing cells in the media depleted of ar-
ginine, a variety of human cancer cells have been found to
be auxotrophic for arginine, depletion of which results in cell
death [7-9]. Further studies have indicated deficiencies in ei-
ther ASS or OCT expression contributes to arginine auxo-
trophy in melanoma and hepatocellular carcinoma [10-13].
Arginine can be degraded by three enzymes: arginase, argin-
ine decarboxylase and arginine deiminase (ADI). Bothtd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Cycle threshold (Ct) of argininosuccinate
synthetase (ASS), ornithine carbamoyl transferase (OCT),
and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) from quantitative real-time PCR in LNCaP, PC-3,
and DU-145 cells
LNCaP PC-3 DU-145
ASS Ct 21.07 26.20 22.77
OCT Ct 40.00 36.82 39.01
GAPDH Ct 16.53 17.21 17.75
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malian cells [2,14]. ADI, an enzyme isolated from Myco-
plasma, catabolizes arginine to citrulline and ammonia.
Pegylated ADI (ADI-PEG20), significantly reduces antigeni-
city of ADI, and has been evaluated clinically in patients with
advanced hepatocellular carcinoma and melanoma [15,16].
The sensitivity of ADI-PEG20 in cancer seems to correspond
with deficient expression of ASS. Resistance to ADI-PEG20
has been identified in hepatocellular carcinoma, melanoma
and prostate cancer cells expressing ASS [10,17,18].
Arginase participates in the urea cycle, and catabolizes ar-
ginine to ornithine and urea [19]. Recombinant human argi-
nase (rhArg) has been developed for arginine deprivation
therapy in cancer, and demonstrated significant cytotoxicity
in hepatocellular carcinoma and melanoma, in vitro and
in vivo [11-13]. In the setting of OCT deficiency, rhArg
eliminates extracellular arginine and results in depletion of
intracellular arginine; however in cells expressing OCT,
intermediate metabolite such as ornithine can be converted
to arginine to avoid intracellular depletion of arginine [20].
It has been demonstrated that OCT deficiency in hepatocel-
lular cancer and melanoma contributes to their sensitivity
of growth inhibition by rhArg [11,13]. In contrast to ADI-
PEG20, the sensitivity to rhArg in hepatocellular carcinoma
and melanoma is independent of ASS expression. Here, we
studied the gene expression profile of OCT and ASS, and
investigated the effects of rhArg in prostate cancer cells.
Results and discussion
Expression of OCT and ASS
Quantitative real-time PCR was performed in prostate
cancer cells to detect mRNA expression of ASS, OCT, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Data were processed and presented with cycle threshold
(Ct) value of each quantitated expression as listed in
Table 1. Housekeeping gene GAPDH was used as a refer-
ence gene for quantitative expression analysis. The Ct is
defined as the number of cycles required for the fluores-
cent signal to cross the threshold level. Ct is a relative
measure of the target mRNA in the PCR, and inversely
proportional to the amount of target mRNA. Ct value of
40 or higher means no amplification due to absent gene
expression. Abundant expression of ASS mRNA was
detected in all three cell lines. Expression of OCT mRNA
was absent in LNCaP, and minimally detected in DU-145
and PC-3.
Cell viability after arginine deprivation by rhArg
We further determined cell viability after 72-h exposure
to rhArg at 0, 0.001, 0.01, 0.1 and 0.5 U/ml. All 3 pros-
tate cancer cell lines were very sensitive to arginine de-
pletion with half maximal inhibitory concentration (IC50)
of rhArg less than or equal to 0.02 U/ml. The IC50 of
rhArg in these 3 prostate cancer cell lines was similar tothe reported values in melanoma and hepatoma cell lines
lacking OCT activity [11,13]. We further investigated the
function of OCT by incubating cells with 0.1 U/ml of
rhArg (>IC50) in the absence and presence of increasing
concentrations of ornithine for 72 h. We expected orni-
thine could rescue rhArg-mediated cytotoxicity if OCT
was expressed and functional. As shown in Figure 1, sup-
plement of ornithine failed to rescue cytotoxicity from
rhArg in all 3 cell lines. These results were in consistent
with deficient OCT gene expression as demonstrated by
quantitative real-time PCR.
Signaling of mammalian target of rapamycin (mTOR)
Autophagy is mediated by lysosomal degradation, and is
an alternative process of cell death [21]. Autophagy is
induced by inhibition of mTOR, which is a key sensor
and regulator of growth signal and environmental stress
[22]. Deprivation of arginine inhibits mTOR pathway
and dephosphorylates downstream targets such as 4E-
BP1 in Chinese hamster ovary and human melanoma
cells [17,23]. To elucidate the mTOR signaling following
arginine depletion by rhArg, we investigated the phos-
phorylation pattern of 4E-BP1. Since our preliminary re-
sult showed citrulline could partially reverse the
cytotoxicity from rhArg, cells were treated with either
citrulline, rhArg, or both for 48 h, followed by Western
blot analysis (Figure 2). Decreased phosphorylation of
4E-BP1 in PC-3 and DU-145 was noted upon exposure
to rhArg, irrespective of citrulline supplement. However,
phosphorylation pattern of 4E-BP1 did not change in
LNCaP. Though inhibition of mTOR by rhArg was
noted in PC-3 and DU-145, the partial reversal of cytoxi-
city by citrulline might not be related to mTOR signaling
since we did not observe any difference in phosphoryl-
ation pattern of 4E-BP1 in the presence or absence of
citrulline.
Measurement of apoptosis
Apoptosis was determined by DNA fragmentation using
TUNEL (terminal deoxynucleotide transferase dUTP
nick end labeling) assay after 36-h co-culture of prostate
cancer cells with rhArg. Purple, green, pink, blue, and
orange histograms indicate levels of DNA fragmentation
Figure 1 Cell viability after exposure to rhArg and various concentrations of orinithine. LNCaP, PC-3 and DU-145 cells were exposed to PBS
(control), rhArg (0.1 U/ml), rhArg (0.1 U/ml) + 1 mM ornithine, rhArg (0.1 U/ml) + 5 mM ornithine, and rhArg (0.1 U/ml) + 10 mM ornithine for 72 h,
then subjected to cell viability assay as mentioned in Methods. Values were reported as the average of 3 experiments with error bars showing
standard error of the mean.
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rhArg, respectively (Figure 3). The results demonstrated
no induction of apoptosis after 36-h exposure of rhArg.
Deficiency in ASS expression renders cellular sensitivity
against ADI-PEG20 in prostate cancer [18]. Both LNCaP
and PC-3 have been shown to express ASS, and are resist-
ant to arginine depletion by ADI-PEG20 [18]. In our study,
all 3 prostate cancer cell lines including LNCaP and PC-3
expressed ASS but had either minimal or absent expres-
sion of OCT, and all 3 lines were highly susceptible to ar-
ginine deprivation by rhArg. Moreover, sensitivity to
rhArg treatment was independent of hormone sensitivity
and not affected by ASS expression in our study.
In human melanoma and prostate cancer cells with
down-regulated ASS expression, treatment of ADI-PEG20
activates adenosine 5′-monophosphate-activated proteinGAPDH
LNCaP    PC-3
Citrulline 
rhArg 
  -   +   -    +      -    +     -
 -    -   +    +      -     -    +
4E-BP1 {
Figure 2 Western blot analysis of 4E-BP1 and GAPDH (as internal con
Hyperphosphorylated (slowly-migrating with higher molecular weight) andkinase (AMPK) due to decreased ATP levels upon arginine
deprivation [18,24]. Activated AMPK further inhibits
mTOR signaling by reducing phosphorylation of 4E-BP1,
and leads to autophagy which is a cellular self-degrading
process mediated by lysosomes. Kim et al. have shown ar-
ginine deprivation by ADI-PEG20 immediately activated
AMPK, and formed intense autophagosome in CWR22Rv1
prostate cancer cells within 90 min of ADI-PEG20 expos-
ure [18]. Onset of caspase-independent apoptosis in ~30%
CWR22Rv1 cells did not occur until after 96-h exposure of
ADI-PEG20. Similar findings of delayed-onset but caspase-
dependent apoptosis after arginine deprivation with 3 to
6 days exposure of either ADI-PEG20 or rhArg were
reported by different groups [13,24].
Common stimuli can induce autophagy and apoptosis,
which occur either in combined manner or sequential                    DU-145
    +           -    +     -    +  
    + -     -    +    +
} 4E-BP1
trol) in the presence of citrulline, rhArg, or both for 48 h.
hypophosphorylated (fast-migrating) 4E-BP1 proteins were detected.
FITC-dUTP
DU-145LNCaP PC-3
Figure 3 Determination of apoptosis by TUNEL assay. Cells were incubated with increasing concentrations of rhArg for 36 h before TUNEL
assay and subsequent analysis by flow cytometer. Purple, green, pink, blue, and orange histograms indicate levels of DNA fragmentation with 0,
0.001, 0.01, 0.1, and 0.5 U/ml rhArg, respectively. Y-axis of histogram represents number of cells analyzed, and x-axis represents function of
fluorescence intensity resulted from binding of FITC-dUTP (fluorescein isothiocyanate tagged deoxyuridine triphosphate) to fragmented DNA.
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between autophagy and apoptosis upon arginine
deprivation with either ADI-PEG20 or rhArg. It is pos-
sible that upon initial arginine deprivation, autophagy is
activated as a defense mechanism to suppress caspase-
dependent apoptosis. As arginine deprivation persists
more than 72 h, autophagy may give in to caspase-
dependent apoptosis in some cell types; whereas in cer-
tain cancer cells, autophagy lasting longer than 24 h may
lead to caspase-independent form of programmed cell
death (autophagic type II cell death) [26].
Using culture media deficient in L-arginine, Wheatley
et al. studied the effects of arginine deprivation in 26 cancer
cell lines, including PC-3 [27]. They demonstrated clear evi-
dence of cell death during second day of arginine
deprivation, and most of PC-3 cells died within 3 days. Fur-
thermore, they observed significantly increased phagosome/
lysosome activity from 24 to 36 h after arginine deprivation,
suggestive of lytic cell death such as autophagy rather than
apoptosis. In this study, we did not identify any significant
apoptosis induction after 36-h exposure of rhArg in all 3
cell lines. Additionally, inhibition of mTOR signaling mani-
fested by decreased phosphorylation of 4E-BP1 was noted
in DU-145 and PC-3 cells after 48-h exposure of rhArg.
Our results are consistent with the report from Wheatley
and others, indicating cell death by arginine deprivation in
DU-145 and PC-3 is due to autophagic cell death.
Both rhArg and ADI are developed for arginine
deprivation in cancer treatment, and currently undergo-
ing clinical investigation. rhArg exhibits significant cyto-
toxicity against cancer cells such as prostate cancer,
melanoma, and hepatocellular carcinoma with OCT defi-
ciency. ADI is effective in tumor cells lacking ASS.
Therefore, cancer can be ADI-resistant but rhArg-sensi-
tive, and vice versa. Personalized medicine can beachieved by examining the expression of OCT and ASS
in cancer specimen before subjecting cancer patients to
arginine deprivation therapy.
Conclusions
rhArg causes significant cytotoxicity in LNCaP, DU-145
and PC-3 prostate cancer cells. The cytotoxicity of rhArg
correlates with deficient OCT gene expression, but is in-
dependent of hormone sensitivity and not affected by
ASS gene expression. Inhibition of mTOR signaling,
manifested by reduced phosphorylation of 4E-BP1, sug-
gests autophagy is involved as alternative cell death
mechanism. rhArg is a promising targeted agent for
prostate cancer, and its activity and mechanism of action
warrant further validation by clinical investigation.
Methods
Cell culture
DU-145, LNCaP and PC-3 human prostate cancer cells
were obtained from the American Type Culture Collection
(Manassas, VA). DU-145 and PC-3 are androgen-inde-
pendent, and LNCaP is androgen-dependent [28]. Cell
lines were maintained in RPMI 1640 medium (Life Tech-
nologies, Grand Island, NY) supplemented with 10% fetal
bovine serum and antibiotics at 37°C in a humidified at-
mosphere of 5% CO2. rhArg was kindly provided by Bio-
Cancer Treatments International Ltd. (Hong Kong,
China), and was characterized as described previously [11].
Quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Life
Technologies), and cDNA was transcribed from total
RNA using SuperScript II RT kit (Life Technologies).
Quantitative real-time PCR was performed in triplicate
on a 7300 Real Time PCR System, using Gene
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(Applied Biosystems, Foster City, CA). Data were pro-
cessed and presented with Ct value of each gene
expression.
Cell viability assay
Cells were plated at 104 cells per well in a 96-well plate
with increasing concentrations of rhArg at 0, 0.001, 0.01,
0.1 and 0.5 U/ml for 72 h at 370 C. Subsequently, cell
viability was determined by a colorimetric method using
CellTiter 96 Aqueous Non-radioactive Cell Proliferation
Assay according to the manufacturer’s protocol (Pro-
mega, Madison,WI).
Protein extraction and Western blot analysis
Protein extraction and Western blot analysis were car-
ried out as previously described with some modifications
[29]. After treatment, cells were washed twice with cold
phosphate-buffered saline, and then resuspended in lysis
buffer (phosphate-buffered saline containing 1% Nonidet
P-40, 0.5% sodium deoxycholate and 0.1% SDS) contain-
ing the protease inhibitors (100 μg/ml phenylmethylsul-
fonyl fluoride, 25 μg/ml aprotinin, 25 μg/ml leupeptin,
10 μg/ml soybean trypsin inhibitor and 1 mM sodium
orthovanadate). The lysate was incubated on ice for
30 min, passed through a 21 gauge needle twice, and
then centrifuged at 15,000 x g for 20 min at 4°C. Protein
concentration was determined using the Bio-Rad protein
assay. Whole cell lysate containing 50 μg of protein from
each sample were used in immunoblotting, and subse-
quently the gels were electroblotted onto PVDF mem-
branes (Immobilon-P, Millipore). Antibodies purchased
from Cell Signaling Technology (Danvers, MA) were
used to detect the proteins of interest. The horseradish
peroxidase conjugated antibodies against mouse, rabbit
and goat IgG were used as secondary antibodies (Sigma-
Aldrich, St. Louis, MO). The secondary antibody binding
was detected by ECL Plus chemiluminescent reagents
and analyzed by Storm image analysis systems (GE
Healthcare Biosciences, Piscataway, NJ).
Apoptosis
Apoptosis was determined by DNA fragmentation using
ApoDirect TUNEL assay kit from Millipore (Billerica,
MA) based on supplier’s instruction. Briefly, 106 Cells were
incubated with increasing concentrations of rhArg for
36 h. Afterwards, DNA breaks were fluorescently labeled
with fluorescein isothiocyanate, and cells were analyzed by
FACScan flow cytometer (Becton Dickinson Biosciences,
San Jose, CA) using Cell Quest Pro software.
Statistical analysis
All experiments have been performed at least twice with
similar results, and the results of one representativeexperiment are reported. Cell viability results are
reported as the average of 3 experiments with error bars
representing standard error of the mean as shown in
Figure 1.
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